Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of solifenacin plus tamsulosin versus monotherapy in men with LUTS associated with BPH
2006-002072-18Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of solifenacin and tamsulosin in benign prostatic hyperplasia (BPH) (7 arms), sponsored by Astellas Pharma. Primary endpoint: Primary efficacy variable. Started Oct 2006; status: completed.
02
Drugs
solifenacintamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2006-002072-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002072-18.